Get the Stockscreener App
25.09
5.78%
-1.54
After Hours:
25.25
0.16
+0.64%
Viking Therapeutics Inc stock is traded at $25.09, with a volume of 4.32M.
It is down -5.78% in the last 24 hours and down -2.94% over the past month.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
See More
Previous Close:
$26.63
Open:
$26.4
24h Volume:
4.32M
Relative Volume:
0.71
Market Cap:
$2.82B
Revenue:
-
Net Income/Loss:
$-99.15M
P/E Ratio:
-26.98
EPS:
-0.93
Net Cash Flow:
$-74.25M
1W Performance:
-3.65%
1M Performance:
-2.94%
6M Performance:
-10.33%
1Y Performance:
-60.26%
1-Day Range:
$25.05
$26.40
1-Week Range:
$24.52
$27.48
52-Week Range:
$18.92
$81.73
Viking Therapeutics Inc Stock (VKTX) Company Profile
Name
Viking Therapeutics Inc
Sector
Industry
Phone
858-704-4660
Address
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
25.09 | 2.99B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
381.87 | 96.56B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.58 | 60.08B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.51 | 61.15B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
711.09 | 44.66B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
328.71 | 36.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-25 | Initiated | Goldman | Neutral |
| Feb-13-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-07-25 | Initiated | Citigroup | Neutral |
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Nov-22-24 | Initiated | B. Riley Securities | Buy |
| Nov-04-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-24 | Initiated | JP Morgan | Overweight |
| Jun-27-24 | Initiated | Morgan Stanley | Overweight |
| May-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-26-24 | Reiterated | Oppenheimer | Outperform |
| Mar-07-24 | Initiated | Jefferies | Buy |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| May-31-23 | Resumed | ROTH MKM | Buy |
| Mar-28-23 | Reiterated | Maxim Group | Buy |
| Mar-17-23 | Initiated | Stifel | Buy |
| Jul-29-21 | Resumed | BTIG Research | Buy |
| May-25-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-05-20 | Initiated | BMO Capital Markets | Outperform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| May-01-20 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-25-19 | Initiated | Stifel | Buy |
| Mar-29-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-14-19 | Reiterated | Maxim Group | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-12-18 | Initiated | B. Riley FBR | Buy |
| Nov-19-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-18-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-18-18 | Reiterated | Maxim Group | Buy |
| Sep-18-18 | Reiterated | Raymond James | Outperform |
| Jul-20-18 | Initiated | SunTrust | Buy |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-01-18 | Reiterated | Laidlaw | Buy |
| May-31-18 | Reiterated | Maxim Group | Buy |
| Mar-26-18 | Resumed | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | Maxim Group | Buy |
| Nov-21-17 | Initiated | ROTH Capital | Buy |
View All
Viking Therapeutics Inc Stock (VKTX) Latest News
Viking Therapeutics (NASDAQ:VKTX) Shares Down 5.8%Here's Why - MarketBeat
Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors - Yahoo Finance
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet - Yahoo Finance
Can Viking Therapeutics Hold Its Edge as Obesity Rivalry Heats Up? - Yahoo Finance
Pfizer Is Buying Weight Loss Biotech Metsera. Here's Why Viking Therapeutics Shareholders May Be Cheering. - MSN
Viking Therapeutics Stock Surges on Promising Obesity Drug Pipeline - AD HOC NEWS
Viking Therapeutics (NASDAQ:VKTX) Trading 6.6% HigherTime to Buy? - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) Trading 7.4% HigherWhat's Next? - MarketBeat
Viking Therapeutics : September 2025 Corporate Presentation - MarketScreener
Are Safety Concerns Around VK2735 Shaping Investor Perceptions of Viking Therapeutics (VKTX)? - simplywall.st
Why Viking Therapeutics Stock Crashed Today - AOL.com
U.S. Capital Wealth Advisors LLC Purchases 27,795 Shares of Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics Shares Dip as Pfizer Chooses Rival Acquisition - AD HOC NEWS
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know - sharewise.com
Pfizer’s $5B Bet on Metsera ($MTSR) vs Viking Therapeutics ($VKTX) - MSN
Strs Ohio Invests $604,000 in Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics at Bernstein Forum: Strategic Moves in Obesity Market - Investing.com
Transcript : Viking Therapeutics, Inc. Presents at Bernstein 2nd Annual Global Healthcare Conference, Sep-23-2025 11 - MarketScreener
Viking Therapeutics at Bernstein Forum: Strategic Moves in Obesity Market By Investing.com - Investing.com UK
Viking Therapeutics Stock Gets Boost From Pfizer-Metsera Deal, Says BTIG — Retail Slams Rivals For Buying ‘Inferior Pipelines’ - Stocktwits
Exchange Traded Concepts LLC Buys 20,296 Shares of Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics: Oral Study Disappoints, Competitor Gets Bought Out (Rating Downgrade) - Seeking Alpha
Why Viking Therapeutics Shares Are Climbing High - TipRanks
BTIG Reiterates Buy Rating for Viking Therapeutics (VKTX) with $125 Target | VKTX Stock News - GuruFocus
BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125 - 富途牛牛
Viking Therapeutics (NASDAQ:VKTX) Earns Buy Rating from BTIG Research - MarketBeat
Viking Therapeutics: Strong Buy Rating Amid Strategic Positioning and Acquisition Potential in the Metabolic Disease Market - TipRanks
Viking Therapeutics (VKTX): Revisiting Valuation After Safety Concerns From Oral Obesity Drug Trial News - simplywall.st
Kingstone Capital Partners Texas LLC Invests $1.37 Million in Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) Stock Price Up 10.6%Here's Why - MarketBeat
Buy Signal: Can Viking Therapeutics Inc maintain its current growth rateJuly 2025 Intraday Action & Precise Swing Trade Alerts - خودرو بانک
Harbor Capital Advisors Inc. Decreases Holdings in Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics, Inc. $VKTX Shares Acquired by Wesbanco Bank Inc. - MarketBeat
Prediction: Viking Therapeutics Stock Will Double in Value Within the Next 12 Months - AOL.com
Merger Talk: Can Viking Therapeutics Inc expand into new marketsIndex Update & Verified Chart Pattern Signals - khodrobank.com
Rate Hike: What are the future prospects of Viking Therapeutics Inc2025 Biggest Moves & Consistent Income Trade Ideas - khodrobank.com
Aug Setups: Is Asure Software Inc stock forming a cup and handle2025 Trading Volume Trends & Verified Stock Trade Ideas - khodrobank.com
Growth Value: Is Viking Therapeutics Inc stock a value trapJuly 2025 Selloffs & Low Risk Growth Stock Ideas - khodrobank.com
Momentum Shift: Is CPIX exposed to political riskJuly 2025 Trade Ideas & Verified Short-Term Plans - خودرو بانک
Published on: 2025-09-18 21:20:40 - خودرو بانک
Analysts Set Viking Therapeutics, Inc. (NASDAQ:VKTX) Target Price at $87.50 - MarketBeat
Biotech Breakouts: 3 Stocks With Massive Upside Potential - Investing.com
Viking Therapeutics (VKTX) Rebounds on Bargain-Hunting. Are You Missing Out? - MSN
Aug PostEarnings: Will Viking Therapeutics Inc. face regulatory challengesMarket Trend Report & Precise Entry and Exit Recommendations - خودرو بانک
Biotech Breakouts: 3 Stocks With Massive Upside Potential - MarketBeat
Is Viking Therapeutics stock a bargain after this week’s sell-off? - MSN
EV Market: How is Viking Therapeutics Inc managing supply chain issuesJuly 2025 News Drivers & Fast Gain Stock Tips - khodrobank.com
Viking Therapeutics, Inc. $VKTX Position Reduced by Voya Investment Management LLC - MarketBeat
Wealth Management Associates Inc. Buys Shares of 9,975 Viking Therapeutics, Inc. $VKTX - MarketBeat
Aug Rallies: Can Viking Therapeutics Inc maintain its current growth rateQuarterly Investment Review & Free Daily Entry Point Trade Alerts - خودرو بانک
Viking Therapeutics Inc Stock (VKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):